

# WELCURE DRUGS AND PHARMACEUTICALS LIMITED

CIN: L68100DL1996PLC227773

Registered Office: Plot No. 55, Office No. 104, First Floor, Vijay Block, Laxmi Nagar, East Delhi, New Delhi, Delhi, India, 110092

Email: [welcuredrugs227@gmail.com](mailto:welcuredrugs227@gmail.com) Website: <https://welcure.co.in/>

---

Date: 06<sup>th</sup> December, 2025

To,

**BSE LIMITED,**

Phirozee Jeejeebhoy Towers,  
Dalal Street, Fort, Mumbai - 400 001

Reference: ISIN- INE331C01025; Scrip Code- 524661; Symbol- WELCURE

**Sub: Outcome of the Meeting of the Board of Directors of Welcure Drugs and Pharmaceuticals Limited held today i.e. Saturday, December 06, 2025**

Dear Sir/Madam,

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the Board of Directors of the Company in its meeting held today i.e. Saturday, December 06, 2025, at the registered office of the Company has inter alia. reviewed and approved various decisions pertaining to the Company's past business operations and investment-related matters.

**1. Execution of Letter of Intent (LOI) with Telexcell Trade PTE LTD, Singapore for Equity Investment**

Reference – Announcement Dated September 03, 2025

BM Intimation Dated September 04, 2025

Outcome of Board Meeting Dated September 27, 2025

**Decision taken by the BOD** - The LOI received was only an indicative, non-binding proposal, subject to due diligence, regulatory clearances, and negotiation of definitive agreements. After preliminary assessment and internal deliberations, the parties could not reach a mutually acceptable framework for the transaction.

Accordingly, the proposed transaction **was not pursued further and now stands closed/aborted**. The Company acted in full compliance with applicable SEBI regulations by making timely and truthful disclosures, including the fact that the proposal was only at an initial non-binding stage.

**2. Proposed Agro-Pharma Research Laboratory & Board Meeting held on 28 August 2025 to consider fund-raising by QIP.**

Reference – BM Intimation Dated August 20, 2025

Outcome of Board Meeting Dated August 28, 2025

**Decision taken by the BOD** - The Company has decided **not to proceed** with the proposed Agro-Pharma Research Laboratory project at this stage. Accordingly, the proposal for fund-raising through QIP is no longer being pursued. This decision has been taken after due consideration of prevailing circumstances and strategic priorities.

# **WELCURE DRUGS AND PHARMACEUTICALS LIMITED**

CIN: L68100DL1996PLC227773

Registered Office: Plot No. 55, Office No. 104, First Floor, Vijay Block, Laxmi Nagar, East Delhi, New Delhi, Delhi, India, 110092

Email: [welcuredrugs227@gmail.com](mailto:welcuredrugs227@gmail.com) Website: <https://welcure.co.in/>

---

## **3. Completion of export-sourcing orders aggregating ₹ 299.91 crore.**

Reference – Announcement Dated July 08, 2025

**Decision taken by the BOD - The Company did not execute the said orders as exports.** Instead, after evaluating logistics, compliance requirements, commercial terms, and the prevailing market scenario, the Company **supplied the same goods in the domestic (local) market to the same parties who were originally intended to receive the export shipments.** Accordingly, the export-sourcing orders stand **completed through domestic sales**, and the Company has recognised the corresponding revenues as per applicable accounting standards.

## **4. Execution of a definitive mandate for third-party sourcing and procurement services aggregating ~₹517 crore with an overseas client, Fortune Sagar Impex Company Limited, Thailand**

Reference – Announcement Dated June 18, 2025

**Decision taken by the BOD -** The proposed transaction relating to the execution of a definitive mandate for third-party sourcing and procurement services aggregating approximately ₹517 crore with Fortune Sagar Impex Company Limited, Thailand, **has not materialised as anticipated.**

**Accordingly, the Company has decided to discontinue and abort the said transaction, and no further action will be taken in this regard.**

The Meeting commenced at 10:00 AM and concluded at 11:00 AM

Please kindly take into your records  
Yours truly,

**For Welcure Drugs and Pharmaceuticals Limited**

**Chintan Didawala Ganpat  
Managing Director  
Din: 11088268**